MergerJul 7, 2026, 07:56 AM
Vivani Medical Subsidiary Cortigent to Merge with ClearOne
AI Summary
Vivani Medical, Inc. announced a definitive merger agreement where its wholly-owned subsidiary, Cortigent, Inc., will merge with a subsidiary of ClearOne, Inc., becoming a wholly-owned subsidiary of ClearOne. Vivani will receive 12,500,000 shares of ClearOne as consideration, with the transaction contingent on ClearOne raising $10,000,000 to $15,000,000 in financing. Separately, Vivani also disclosed a new agreement with Novo Nordisk for the evaluation of its NPM-139 semaglutide implant for chronic weight management, with a Phase 1 study anticipated to start in mid-2026.
Key Highlights
- Vivani Medical's wholly-owned subsidiary, Cortigent, Inc., will merge with a subsidiary of ClearOne, Inc.
- Vivani Medical will receive 12,500,000 shares of ClearOne, Inc. as merger consideration.
- The merger is contingent on ClearOne, Inc. raising $10,000,000 to $15,000,000 in financing.
- Vivani Medical will designate four of the five board members for the combined company.
- Vivani Medical entered an agreement with Novo Nordisk to evaluate its NPM-139 semaglutide implant.
- A Phase 1 study for the NPM-139 semaglutide implant is expected to begin in mid-2026.
Price Impact
More from VANI